Final phase 2 analysis of surufatinib plus camrelizumab, nab-paclitaxel and gemcitabine in first-line metastatic pancreatic cancer

albumin-bound paclitaxel - Generic mfg.

Sulanda (surufatinib) - Hutchmed

gemcitabine - Generic mfg.

AiRuiKa (camrelizumab) - Elevar Therapeutics

https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal_1/print/presentation/1816

Shukui Qin; Jihui Hao; Chen Xun; Yanqiao Zhang; Baiyong Shen; Zhongmin Zhang; Heshui Wu; Xiaobing Chen; Zhenyang Liu; Huikai Li; Rufu Chen; Jianwei Yang; He Tian; Yong Li; Enxiao Li; Yiping Mou; Xiang Wang; Yanru Qin; LiMing Gao; Songhua Fan

Jul 17, 2026